Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : Naptumomab estafenatox (NAP; ABR-217620) is a recombinant fusion protein consisting of a chimeric staphylococcal enterotoxin A/E (SEA/SEE) superantigen with several additional substitutions that is linked to a Fab moiety recognizing a tumor-associated gl...
Product Name : ABR-217620
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
January 06, 2022
Lead Product(s) : Naptumomab Estafenatox,Durvalumab
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Naptumomab Estafenatox, the company’s lead TTS molecule, binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells.
Product Name : ABR-217620
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
April 19, 2021
Lead Product(s) : Naptumomab Estafenatox,Durvalumab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naptumomab Estafenatox,Durvalumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : $45.0 million
Deal Type : Series C Financing
Israeli biotech NeoTX lands $45M series C for combo I-O cancer trials
Details : The company plans to complete the dose escalation phase of the Phase 1b trial of naptumomab estafenatox in combination with durvalumab and continue to develop our patented STR platform.
Product Name : ABR-217620
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
February 19, 2020
Lead Product(s) : Naptumomab Estafenatox,Durvalumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : $45.0 million
Deal Type : Series C Financing
Reset All
